CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation.

Abstract

Background: Recent evidence suggests a link between glycoprotein non-metastatic melanoma protein B (GPNMB) and Parkinson's disease (PD) pathogenesis. Although elevated plasma GPNMB levels associated with disease severity have been reported in PD, cerebrospinal fluid (CSF) alterations remain elusive.

Objective: To explore CSF GPNMB alterations and its clinical significance in PD.

Methods: This study enrolled 118 sporadic PD patients and 40 controls. We examined the potential associations between CSF GPNMB levels and the clinical characteristics or biomarkers of neurodegenerative pathogenesis.

Results: PD patients had higher CSF GPNMB levels than controls (p = 0.0159). In the PD group, CSF GPNMB levels correlated with age (age at examination: r_s= 0.2511, p = 0.0061; age at onset: r_s= 0.2800, p = 0.0021) and the severity of motor and cognitive dysfunction (MDS-UPDRS III score: r_s= 0.1998, p = 0.0347; Mini-Mental State Examination score: r_s= -0.1922, p = 0.0370). After correcting for multiple comparisons, the correlation with age at onset remained significant. CSF GPNMB levels were also positively correlated with CSF soluble triggering receptor expressed on myeloid cells 2 (sTREM2) levels in both the PD (r_s= 0.3582, p < 0.0001) and control (r_s= 0.4743, p = 0.0023) groups. Furthermore, multiple regression analysis revealed CSF sTREM2 level as the strongest determinant of CSF GPNMB levels in the PD group (t-value = 3.49, p = 0.0007).

Conclusions: Elevated CSF GPNMB levels, linked with age and microglial activation, may be a valuable marker for understanding the interplay between aging, neuroinflammation, and PD pathology.